Twenty-five states are backing the federal government in litigation before two federal appeals courts over drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.
Category: Twitter
In a major blow to the 340B provider community, U.S. Rep. David McKinley, the leading voice for the 340B program in the House Republican caucus, was defeated Tuesday in the West Virginia Republican primary. McKinley will remain in
…
Six groups that support patients with HIV/AIDS and viral hepatitis and their caregivers issued a joint statement yesterday criticizing drug manufacturers AbbVie, Gilead, and Merck’s conditions on 340B pricing on hepatitis C medications.
Please
At least 48 hospitals lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic and are seeking reinstatement to the 340B program, HRSA says.
Please Login or Become a Paid
Many National Cancer Institute (NCI) designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially,” according to new research in JAMA Internal Medicine.
…
Many National Cancer Institute (NCI) designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially,” according to new research in JAMA Internal Medicine.
…
A nationally prominent drug policy expert and two colleagues at Harvard Medical School have written in JAMA how Congress could end the fight over 340B contract pharmacy and enhance 340B program integrity.
Please Login
A federal district judge in Indianapolis last week responded to a higher court’s directive and entered an amended partial final judgement in drug manufacturer Lilly’s 340B contract pharmacy lawsuit.
Please Login or Become a Paid Subscriber
Drug manufacturer Sanofi has made two major changes to its conditions on 340B pricing when health centers and certain hospitals and use contract pharmacies, a company spokesperson confirms.
Please Login or Become a Paid Subscriber to
Bristol Myers Squibb has disclosed its terms of use for the drug claims data that providers must give it in exchange for access to 340B pricing on BMS’s oral oncology drugs Revlimid, Pomalyst, and Thalomid.